Cano-Ortiz Antonio, Sánchez-Ventosa Álvaro, González-Cruces Timoteo, Villalba-González Marta, Aguilar-Salazar Francisco Javier, Prados-Carmona Juan J, Díaz-Mesa Vanesa, Villarrubia Alberto
Department of Ophthalmology, Hospital Arruzafa, 14012 Cordoba, Spain.
Department of Health and Biomedical Sciences, Universidad Loyola Andalucía, 41704 Sevilla, Spain.
J Clin Med. 2025 May 26;14(11):3717. doi: 10.3390/jcm14113717.
To evaluate the clinical performance and optical quality of a non-diffractive extended-depth-of-focus (EDOF) intraocular lens (IOL), Asqelio™ EDOF (models ETLIO130C/ETPIO130C), in patients undergoing cataract surgery or refractive lensectomy. This prospective observational, case-control study included patients bilaterally implanted with either the Asqelio™ EDOF IOL (Study Group) or the spherical monofocal TECNIS 1-Piece ZCB00 IOL (Control Group). The postoperative outcomes-at 3 months after surgery-included visual acuities at multiple distances, refraction, contrast sensitivity, the optical scatter index (OSI), wavefront aberrations, and patient-reported outcomes (Catquest-9SF and a quality-of-vision questionnaire). Twenty-three patients (46 eyes) in the Asqelio™ EDOF group and 17 patients (34 eyes) in the monofocal control group were enrolled. Postoperatively, 91% of eyes in the EDOF group were within ±0.50 D of the intended spherical equivalent. The binocular uncorrected distance, intermediate, and near visual acuities were 0.00 ± 0.09, 0.13 ± 0.12, and 0.32 ± 0.15 logMAR, respectively. Contrast sensitivity and OSI values were similar between the study and control groups ( > 0.05). Higher-order aberrations were significantly lower in the EDOF group ( < 0.001), but values in both groups were clinically low. No adverse events were reported. Most patients expressed high satisfaction and reported few visual disturbances. The Asqelio™ EDOF IOL provided good refractive predictability, effective uncorrected vision across distance and intermediate ranges, and high patient satisfaction. Contrast sensitivity and optical scatter were comparable to monofocal implants. This lens can be considered a valuable option for patients seeking an extended range of functional vision with minimal side effects.
为评估非衍射型扩展焦深(EDOF)人工晶状体(IOL)Asqelio™ EDOF(型号ETLIO130C/ETPIO130C)在接受白内障手术或屈光性晶状体切除术患者中的临床性能和光学质量。这项前瞻性观察性病例对照研究纳入了双侧植入Asqelio™ EDOF人工晶状体(研究组)或球面单焦点TECNIS 1-Piece ZCB00人工晶状体(对照组)的患者。术后3个月的结果包括多个距离的视力、屈光、对比敏感度、光学散射指数(OSI)、波前像差以及患者报告的结果(Catquest-9SF和视觉质量问卷)。Asqelio™ EDOF组纳入了23例患者(46只眼),单焦点对照组纳入了17例患者(34只眼)。术后,EDOF组91%的眼的球镜等效度在预期值±0.50 D范围内。双眼未矫正远、中、近视力的对数最小分辨角(logMAR)分别为0.00±0.09、0.13±0.12和0.32±0.15。研究组和对照组的对比敏感度和OSI值相似(>0.05)。EDOF组的高阶像差显著更低(<0.001),但两组的值在临床上都较低。未报告不良事件。大多数患者表示高度满意,且报告的视觉干扰较少。Asqelio™ EDOF人工晶状体提供了良好的屈光可预测性、有效的远近中距离未矫正视力以及较高的患者满意度。对比敏感度和光学散射与单焦点植入物相当。对于寻求具有最小副作用的扩展功能性视力范围的患者,这种人工晶状体可被视为一种有价值的选择。